Orange Book product · Generic (ANDA)
CITALOPRAM HYDROBROMIDE
CITALOPRAM HYDROBROMIDE
At a glance
Mar 13, 2026
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Mar 13, 2026
3 mo ago
Today
Exclusivity ends · CGT
FDA marketing exclusivity
Sep 16, 2026
in 3 mo
Pharmaceutical detail
Active ingredient
CITALOPRAM HYDROBROMIDE
Strength
EQ 30MG BASE
Dosage form
CAPSULE
Route
ORAL
TE code
AB
Application
ANDA 219985
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of CITALOPRAM HYDROBROMIDE
- 2022CITALOPRAM HYDROBROMIDEBrand (NDA)
NDA 215428 · ALMATICA
- 2005CITALOPRAM HYDROBROMIDEBrand (NDA)
NDA 021763 · BIOVAIL LABS INTL
- 2000CELEXABrand (NDA)
NDA 020822 · ABBVIE
- 1999CELEXABrand (NDA)
NDA 021046 · FOREST LABS
- 2015CITALOPRAM HYDROBROMIDEGeneric (ANDA)
ANDA 205407 · JUBILANT GENERICS
- 2015CITALOPRAM HYDROBROMIDEGeneric (ANDA)
ANDA 201450 · HETERO LABS LTD III
- 2009CITALOPRAM HYDROBROMIDEGeneric (ANDA)
ANDA 077654 · GLENMARK PHARMS LTD
- 2008CITALOPRAM HYDROBROMIDEGeneric (ANDA)
ANDA 077141 · NATCO PHARMA LTD
- 2007CITALOPRAM HYDROBROMIDEGeneric (ANDA)
ANDA 078216 · TORRENT PHARMS
- 2007CITALOPRAM HYDROBROMIDEGeneric (ANDA)
ANDA 077668 · PHARMOBEDIENT
- 2006CITALOPRAM HYDROBROMIDEGeneric (ANDA)
ANDA 077289 · AMNEAL PHARMS NY
- 2006CITALOPRAM HYDROBROMIDEGeneric (ANDA)
ANDA 077534 · INVAGEN PHARMS
Marketing exclusivity (1)
- CGTFDA marketing exclusivity
Sep 16, 2026
in 3 mo
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
